Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Recalcitrant Wet Age-related Macular Degeneration: early-phase trial registry

A small indexed set (1 trial) with no open enrollment listed right now.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · none currently recruiting · #11,370 of 28,707 conditions by registered trial count

Recalcitrant Wet Age-related Macular Degeneration: 1 US clinical trial tracked, none currently recruiting.

Recalcitrant Wet Age-related Macular Degeneration is the subject of 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Northern California Retina Vitreous Associates, running 1 of these trials.

Enrollment posture brief

Registry condition recalcitrant-wet-age-related-macular-degeneration

OPEN 0 | RECR 0% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Recalcitrant Wet Age-rel (th…0%
Open-enrollment share among volume-matched conditions near Recalcitrant Wet Age-related Macular Degeneration

Recalcitrant Wet Age-related Macular Degeneration has no open enrollment in this registry pull (1 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Recalcitrant Wet Age-related Macular Degeneration on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Recalcitrant Wet Age-related Macular Degeneration is recruiting below its size-band peers.

    0 of 1 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Named interventions

Most-linked intervention names on Recalcitrant Wet Age-related Macular Degeneration records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Ranibizumab Drug
1 trials

US sites by state

Facility locations filed on Recalcitrant Wet Age-related Macular Degeneration trials. A trial with sites in several states counts in each.

California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Recalcitrant Wet Age-related Macular Degeneration page

1 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Recalcitrant Wet Age-related Macular Degeneration trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Northern California Retina Vitreous Associates sponsors the most Recalcitrant Wet Age-related Macular Degeneration trials on record, review their full trial history before evaluating a specific study. See Northern California Retina Vitreous Associates's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recalcitrant Wet Age-related Macular Degeneration condition card totals 1 registered trials; most-linked intervention Ranibizumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.